BioSpace News Archive

ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation at the 2024 American Society of Cancer Oncology Annual Meeting being held in Chicago from May 31-June 4, 2024.

GSK plc announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating belantamab mafodotin, in combination with pomalidomide plus dexamethasone, versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.

A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.

Ascentage Pharma announced that it has released updated data of its novel drug candidate AGP-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor, in patients with non-small-cell lung cancer in a poster presentation at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.

BioCryst Pharmaceuticals, Inc. announced new real-world evidence showing that patients with hereditary angioedema who have normal C1-inhibitor level and function had a reduction in monthly attack rates after starting oral, once-daily ORLADEYO®.

Precede Biosciences shared two scientific poster presentations from the 2024 American Society of Clinical Oncology Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois.

Flamingo Therapeutics announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology taking place in Chicago, Illinois.

Puma Biotechnology, Inc. announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor resistant, human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer at the 2024 American Society of Clinical Oncology Annual Meeting currently being held in Chicago.

Seer, Inc. announced that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to date utilizing the Seer Proteograph™ Product Suite and Thermo Fisher Scientific’s Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer.

Genmab A/S announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of follicular lymphoma.